Memo (Galantamine Hydrobromide)

Galantamine works by reversibly inhibiting the enzyme acetylcholinesterase, which breaks down acetylcholine. This inhibition raises acetylcholine levels in synapses, supporting neuronal communication. Additionally, galantamine modulates nicotinic acetylcholine receptors, further enhancing cholinergic signaling important for learning and memory.

The dosage of Memo is individualized by the prescribing clinician. Treatment typically begins with a low dose that is gradually increased based on tolerability and clinical response. The prescriber determines the final regimen according to the patient’s condition and renal or hepatic function.

The safety of galantamine in pregnancy and lactation has not been established. It is classified as a pregnancy category with unknown risk, and use is generally avoided unless the potential benefit to the mother outweighs any possible risk to the fetus or infant.

To order Memo, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Memo (galantamine) belongs to the acetylcholinesterase inhibitor class, similar to donepezil and rivastigmine. Compared with donepezil, galantamine also modulates nicotinic receptors, which may offer additional cognitive benefits for some patients. Rivastigmine is available as a transdermal patch, while galantamine is administered orally, providing a different dosing flexibility.

Memo should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the tablet container tightly closed and out of reach of children. Do not store in a refrigerator or freezer.

Memo is taken orally as a tablet. The tablet should be swallowed whole with a full glass of water, preferably with meals to reduce gastrointestinal discomfort. The exact timing and frequency are determined by the prescribing clinician based on the individual treatment plan.

Serious risks include severe bradycardia, which can cause fainting or require medical intervention, hepatotoxicity indicated by elevated liver enzymes, and rare seizures. Patients should promptly report symptoms such as unusually slow heart rate, yellowing of the skin or eyes, or convulsive episodes to their healthcare provider.

Memo is contraindicated in patients with known hypersensitivity to galantamine or any excipients, those with severe hepatic impairment, and individuals with significant cardiac conduction disorders such as sick‑sinus syndrome or advanced atrioventricular block unless a pacemaker is in place.